Fluvastatin and fluvastatin extended release: a clinical and safety profile. (Q35879055)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15350166 AND SRC:MED&resulttype=core&format=json

1 January 2020

review article

1 reference

title

Fluvastatin and fluvastatin extended release: a clinical and safety profile (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15350166 AND SRC:MED&resulttype=core&format=json

1 January 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15350166 AND SRC:MED&resulttype=core&format=json

1 January 2020

author name string

Hallvard Holdaas

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15350166 AND SRC:MED&resulttype=core&format=json

1 January 2020

publication date

1 September 2004

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15350166 AND SRC:MED&resulttype=core&format=json

Expert Review of Cardiovascular Therapy

1 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15350166 AND SRC:MED&resulttype=core&format=json

1 January 2020

volume

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15350166 AND SRC:MED&resulttype=core&format=json

1 January 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15350166 AND SRC:MED&resulttype=core&format=json

1 January 2020

page(s)

641-652

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15350166 AND SRC:MED&resulttype=core&format=json

Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations. Monitoring trends and determinants in cardiovascular disease.

1 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1586/14779072.2.5.641

Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14779072.2.5.641

Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14779072.2.5.641

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14779072.2.5.641

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14779072.2.5.641

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14779072.2.5.641

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14779072.2.5.641

Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14779072.2.5.641

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14779072.2.5.641

Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14779072.2.5.641

Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14779072.2.5.641

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14779072.2.5.641

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14779072.2.5.641

Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14779072.2.5.641

The effect of gemfibrozil on the pharmacokinetics of rosuvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14779072.2.5.641

FDA adverse event reports on statin-associated rhabdomyolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14779072.2.5.641

Regulation of plasma cholesterol by lipoprotein receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14779072.2.5.641

Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14779072.2.5.641

Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14779072.2.5.641

Rho GTPases and signaling networks

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14779072.2.5.641

Fluvastatin: effects beyond cholesterol lowering

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14779072.2.5.641

Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14779072.2.5.641

Fluvastatin reduces tissue factor expression and macrophage accumulation in carotid lesions of cholesterol-fed rabbits in the absence of lipid lowering

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14779072.2.5.641

HMG-CoA reductase inhibitors reduce interleukin-6 synthesis in human vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14779072.2.5.641

Effect of fluvastatin on endothelium-dependent brachial artery vasodilation in patients after renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14779072.2.5.641

Effect of a 3-year therapy with the 3-hydroxy-3-methylglutaryl coenzyme a reductase-inhibitor fluvastatin on endothelial function and distensibility of large arteries in hypercholesterolemic renal transplant recipient

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14779072.2.5.641

Fluvastatin reduces atherogenic lipids without any effect on native endothelial function early after kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14779072.2.5.641

Fluvastatin therapy improves microcirculation in patients with hyperlipidaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14779072.2.5.641

The effect of pravastatin on acute rejection after kidney transplantation--a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14779072.2.5.641

Effect of pravastatin on outcomes after cardiac transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14779072.2.5.641

Effect of fluvastatin on acute renal allograft rejection: a randomized multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14779072.2.5.641

Interactions between cyclosporin and lipid-lowering drugs: implications for organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14779072.2.5.641

Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14779072.2.5.641

Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14779072.2.5.641

Safety, tolerability, and pharmacokinetics of an extended-release formulation of fluvastatin administered once daily to patients with primary hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14779072.2.5.641

Disposition of fluvastatin, an inhibitor of HMG-COA reductase, in mouse, rat, dog, and monkey

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14779072.2.5.641

Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14779072.2.5.641

Clinical pharmacokinetics of fluvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14779072.2.5.641

Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and ( )-3R,5S-fluvastatin in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14779072.2.5.641

Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14779072.2.5.641

Evidence for a role of human organic anion transporters in the muscular side effects of HMG-CoA reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14779072.2.5.641

Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14779072.2.5.641

Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14779072.2.5.641

Mechanistic studies on metabolic interactions between gemfibrozil and statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14779072.2.5.641

Updated clinical safety experience with fluvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14779072.2.5.641

Efficacy and tolerability of fluvastatin extended-release delivery system: a pooled analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14779072.2.5.641

Effect of fluvastatin slow-release on low density lipoprotein (LDL) subfractions in patients with type 2 diabetes mellitus: baseline LDL profile determines specific mode of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14779072.2.5.641

Circulation impact factor is highest ever.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14779072.2.5.641

Cerivastatin and reports of fatal rhabdomyolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14779072.2.5.641

Long-term safety of hepatic hydroxymethyl glutaryl coenzyme A reductase inhibitors: the role of metabolism-monograph for physicians

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14779072.2.5.641

Comparative tolerability of the HMG-CoA reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14779072.2.5.641

Frequency of creatine kinase elevation during treatment with fluvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14779072.2.5.641

Frequency of creatine kinase elevation during treatment with fluvastatin in combination with fibrates (bezafibrate, fenofibrate, or gemfibrozil).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14779072.2.5.641

Fluvastatin reduces cardiac mortality in patients with coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14779072.2.5.641

Immunomodulatory effects of statins: mechanisms and potential impact on arteriosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14779072.2.5.641

Effect of fluconazole on plasma fluvastatin and pravastatin concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/14779072.2.5.641

21 January 2018

Identifiers

DOI

10.1586/14779072.2.5.641

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15350166 AND SRC:MED&resulttype=core&format=json

1 January 2020

1 reference